Life Scientist > Health & Medical

Award for cancer immunology science

22 April, 2002 by Tanya Hollis

Research proving that the immune system roams the body hunting out malignancies has led to an international award for a Melbourne scientist.

Aston hired to help transform AustCancer

17 April, 2002 by Daniella Goldberg

Perth-based Australian Cancer Technology has appointed Dr Roger Aston, former Peptech CEO, to Executive Chairman to oversee their joint ventures, with London-based drug discovery services company Biofocus, and other cancer therapy projects.

Fear, regulatory black hole block diabetes trials

09 April, 2002 by Daniella Goldberg

Stringent guidelines and incomplete regulatory guidelines at home are forcing Australian and New Zealand biotechs offshore to test their novel diabetes treatments. But they are discovering that not everyone wants them.

Leukaemia research gives Bresagen gets a decade of market exclusivity

09 April, 2002 by Tanya Hollis

Bresagen (ASX: BGN) has been granted a 10-year head start on the development of its anti-leukaemia drug E21R.

Garvan spin-off to trial monoclonal targets

08 April, 2002 by Daniella Goldberg

G2 Therapies, a recent spin-off company from the Garvan Institute of Medical Research, will be launching into clinical trials of monoclonal targets to treat inflammatory diseases and cancer after raising $3.3 million in a first-round venture capital funding.

Gene cream offers hope for psoriasis sufferers

27 March, 2002 by Tanya Hollis

A Melbourne research group has become one of the first in the world to create a gene cream that successfully penetrates psoriasis lesions.

Metabolic to develop osteoporosis treatment

26 March, 2002 by Tanya Hollis

Metabolic Pharmaceuticals has announced a trans-Tasman licensing deal and research collaboration to develop a new osteoporosis treatment.

Aussie heart test given the go-ahead

26 March, 2002 by Tanya Hollis

An Australian-developed, non-invasive test to measure arterial stiffness and heart function has been given the official nod from the United States.

Nerve drug fails in Phase II

22 March, 2002 by Tanya Hollis

A drug intended to reduce peripheral nerve damage in cancer patient has failed in a clinical trial.

Queensland gets closer to Texas

20 March, 2002 by Pete Young

Closer ties between a Texas biomedical research powerhouse and Queensland biotech institutes have been foreshadowed by Queensland Premier Peter Beattie.

Bug DNA used to fight disease

20 March, 2002 by Pete Young

Australian scientists are claiming a world-first technique for using DNA 'fingerprints' of bacteria as an early warning system against disease epidemics.

Polartechnics promises more accurate cervical screen

19 March, 2002 by Daniella Goldberg

A cervical screening product that its developer claims is more accurate than the conventional pap smear in detecting earlier grades of pre-cancer will be on the European market within the next few months, and in Australia by the end of the year.

Biotron sacrifices profits for R&D

15 March, 2002 by Tanya Hollis

Biotechnology licensing company Biotron (ASX:BIT) has sacrificed profits in favour of ramping up research and development expenditure into its cancer diagnostic and anti-HIV drug programs.

Sirtex looks to Europe following FDA success

12 March, 2002 by Daniella Goldberg

Small particle technology company Sirtex Medical is seeking European approval for its liver cancer treatment, following last week's announcement it had been approved by the US Food and Drug Administration.

Epilepsy breakthrough for Adelaide researchers

11 March, 2002 by Melissa Trudinger

A surprise finding by a team of Adelaide scientists has provided the first evidence that the same gene on the X-chromosome may be responsible for some forms of both epilepsy and intellectual disability.

  • All content Copyright © 2021 Westwick-Farrow Pty Ltd